-
The net profit of pharmaceutical stocks soared from 50 million to 16 billion, and only 3 companies lost money
Time of Update: 2022-10-25
Jiuan Medical soared 300 times to become the "growth king", the net profit soared from 50 million yuan to 16 billion yuan, the CXO leading performance soared, and chain giants such as Laobai, Da Shenlin and Yifeng steadily climbed.
-
2023 China (Beijing) International Electronic Scale Exhibition
Time of Update: 2022-10-25
2023 China (Beijing) International Electronic Scale Exhibition China (Beijing) International Electronic Weighing Instrument Exhibition2023 【Basic Information】 When: June 16-18, 2023 Venue: Beijing Et
-
Pharmaceutical companies are laying out shingles vaccines, and how is the current research and development progress
Time of Update: 2022-10-25
On October 21, multinational pharmaceutical company GlaxoSmithKline (GSK) announced positive interim results in the expansion of its recombinant herpes zoster vaccine "Xin'anlishi".
On October 21, multinational pharmaceutical company GlaxoSmithKline (GSK) announced positive interim results in the expansion of its recombinant herpes zoster vaccine "Xin'anlishi".
-
How will the pharmaceutical equipment industry develop in the future? Four trends have long been known
Time of Update: 2022-10-25
com) According to the public data of listed pharmaceutical equipment, we can see that in the past two years, the performance of pharmaceutical machinery enterprises represented by Chutian Science and Technology, Dongfulong and other heads in China has achieved steady growth, and the overall prosperity of the industry is relatively high.
-
The expansion of the large catalogue of Chinese medicinal materials is about to enter the market by China Resources and Jiang Zhongzhong
Time of Update: 2022-10-25
Second, set off a new product development boom China's current medicinal and food homologous products mostly enter the market in the form of traditional Chinese medicine pieces or medicinal diets, which can basically meet the daily needs of consumers, but due to simple preparation and low technical content, the added value of products is low and the core competitiveness is insufficient.
-
During the year, more than 1,000 listed companies set off a wave of buybacks, and pharmaceutical companies became "frequent customers"
Time of Update: 2022-10-25
In terms of the number of repurchases, WuXi Biologics has been active in repurchases, with a total of eight repurchases in the past month, with a total capital contribution of nearly HK$1 billion and more than 20 million shares repurchased (data as of the market close on October 14).
-
The performance of Kun Pharmaceutical Group has grown, and the upward pressure on raw materials has increased!
Time of Update: 2022-10-25
Baishu, Henan and other production areas began to produce new, it is expected that this year's new goods output is not large, the market source of small quantities continues to be good, merchants actively purchase and sell, the market has maintained stable operation in recent times, the price of Anhui biennial tablets is between 32-33 yuan, and the market is optimistic.
-
Schneider Electric Live Preview Dry Goods from Clean Environment to Process Automation is coming!
Time of Update: 2022-10-25
With the rapid development of emerging technologies such as cloud computing, AI, 5G, and the Internet of Things, as well as the continuous introduction of strategies such as "Industry 4. 0" and "Made
-
A number of CXO heads disclosed "eye-catching" report cards in the first three quarters, and the industry is prosperous
Time of Update: 2022-10-25
Zhaoyan New Drug issued a performance forecast announcement on the evening of October 18, and it is expected to achieve a net profit attributable to the parent in the first three quarters of about 607 million to 657 million yuan, a year-on-year increase of about 144.
-
$610 million! Leading multinational pharmaceutical manufacturers launched large acquisitions
Time of Update: 2022-10-25
Currently, Akoouos is developing viral gene therapy for the treatment of inner ear disorders, including sensorineural hearing loss.
Currently, Akoouos is developing viral gene therapy for the treatment of inner ear disorders, including sensorineural hearing loss.
-
The first generic drug has become a place for pharmaceutical companies, and a large number of drugs will be the first imitation
Time of Update: 2022-10-25
In terms of generic drugs, in addition to Shuanghe Pharmaceutical, which reported production this time, Sichuan Guowei Pharmaceutical submitted a marketing application in November 2021, which is still under review and approval.
-
Invisible orthodontics will also be collected! Will the market landscape change?
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Due to the high price of dental implants, the news and progress of dental implant collection in the past two years have attracted the attention of consumers.
-
Biotech Survive Broken Tail! Stone Medicine, Zhongsheng, GSK, BMS, Pfizer throw olive branches! Is it time to dig the bottom?
Time of Update: 2022-10-25
01 Go in both directions, each take what you need Biotech joins hands with Big Pharma to survive the winter On April 1 this year, Nature Reviews Drug Discovery published a statistical article on the field of innovative drugs in China, and the content analysis pointed out that as of July 1, 2021, there were 2,251 drugs (including drugs and biological products) under development in all therapeutic areas in China, including 418 first-in-class, 473 fast-follower, and 923 me-too.
-
Since the third quarter, investment and financing in the field of medical equipment have been hot, and the financing scale of some enterprises has exceeded 5 billion yuan
Time of Update: 2022-10-25
On October 14, Fujian Provincial Joint Procurement Center for Pharmaceuticals and Devices issued an announcement "Laparoscopic Cutting Kiss/Suture Instrument Medical Consumables Inter-provincial Alliance Centralized Procurement Announcement (No. 1)", the overall price reduction is relatively moderate, import manufacturers are expected to report the volume to be seized by domestic manufacturers, domestic substitution is expected to accelerate.
-
Qilu exploded! 30 Class 1 new drugs dominate, and 13 blockbuster varieties have been approved
Time of Update: 2022-10-25
Since the beginning of this year, Qilu Pharmaceutical has submitted clinical applications for 6 Class 2 improved new drugs, including risperidone oral dissolving film, lenvatinib mesylate capsules, atropine sulfate eye drops, semeglutide injection, tetrahexose ganglioside sodium monosialic acid injection, oseltamivir oral lytic membrane phosphate.
-
Investment and layout of artificial intelligence have become an important part of the competition of pharmaceutical giants
Time of Update: 2022-10-25
Therefore, in order to improve R&D efficiency and reduce R&D investment, with the continuous development of science and technology in recent years, more and more companies and researchers have begun to apply "artificial intelligence" to pharmaceutical R&D and market, trying to further improve the success rate of new drug research and development through artificial intelligence technology AI algorithms, reduce manufacturing costs and R&D time.
-
More than a year after taking office, the CEO of this pharmaceutical company joined the "resignation army"!
Time of Update: 2022-10-25
On October 21, Ridge Pharma announced that Mr. Hua Fengmao applied to resign as a director, chief executive officer (CEO), special committee of the board of directors and subsidiaries of the company due to personal reasons.
-
Has the "proportion of medicine" changed its taste? Hospital assessment urgently needs to be refined!
Time of Update: 2022-10-25
The reform of medical insurance payment methods from charging by service items to paying for budget management is in full swing across the country. The basic principle of the reform is to partially s
-
Will tumor genetic testing be included in centralized procurement? The official reply is coming!
Time of Update: 2022-10-25
In addition, whether tumor genetic testing projects will be included in the procurement with quantity, the National Medical Insurance Administration said: "Tumor genetic testing is a medical service project, and according to the current policy, the basic medical services provided by public medical institutions are subject to government guidance prices.
-
The innovation achievements of pharmaceutical companies have gradually emerged, and the sales of a number of new Chinese medicine drugs have grown steadily
Time of Update: 2022-10-25
The sales of three innovative patented traditional Chinese medicines, Tongxinluo capsules, Sansong Yangxin capsules and Qilang Qiangxin capsules, which are laid out by Yiling Pharmaceutical in the field of cardiovascular and cerebrovascular diseases, have also steadily increased in recent years, with compound growth rates of 9.
